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Background: To analyze and compare the economic outcomes of adjuvant chemotherapy with capecitabine plus
oxaliplatin (referred to as the XELOX strategy) and of S-1 (the S-1 strategy) for gastric cancer patients after D2
gastrectomy.
Methods: A Markov model was developed to simulate the lifetime disease course associated with stage II or III
gastric cancer after D2 gastrectomy. The lifetime quality-adjusted life years (QALYs), associated costs, and
incremental cost-effectiveness ratios (ICERs) were estimated. The clinical data were derived from the results of pilot
studies. Direct costs were estimated from the perspective of the Chinese healthcare system, and the utility data
were measured from end-point observations of Chinese patients. Sensitivity analyses were used to explore the
impact of uncertainty on the model’s outcomes.
Results: The combined adjuvant chemotherapy strategy with XELOX yielded the greatest increase in QALYs over
the course of the disease (8.1 QALYs compared with 7.8 QALYs for the S-1 strategy and 6.2 for surgery alone). The
incremental cost per QALY gained using the XELOX strategy was significantly lower than that for the S-1 strategy
($3,502 vs. $6,837, respectively). The results were sensitive to the costs of oxaliplatin and the hazard ratio of
relapse-free survival.
Conclusion: The observations reported herein suggest that adjuvant therapy with capecitabine plus oxaliplatin is
a highly cost-effective strategy and more favorable treatment option than the S-1 strategy in patients with stage II
or III gastric cancer who have undergone D2 gastrectomy.
Keywords: Gastric cancer, Adjuvant chemotherapy, Economic analysis, Cost-effectivenessBackground
Despite the declining incidence of gastric cancer, it re-
mains the second leading cause of cancer deaths world-
wide, with approximately 736,000 deaths and 988,000 new
cases each year [1]. East Asia, including China, Korea, and
Japan, has one of the highest incidences and mortality
rates of gastric cancer [2-4]. D2 gastrectomy is the most
widely used surgical treatment for localized gastric cancer,
and long-term follow-up has demonstrated a reduction in
gastric cancer-related deaths in patients who have under-
gone D2 gastrectomy compared with D1 gastrectomy* Correspondence: zhaogangrjgs@126.com
5Department of General Surgery, Ren Ji Hospital, School of Medicine,
Shanghai Jiao Tong University, Shanghai, China
Full list of author information is available at the end of the article
© 2014 Wu et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.[5-7]. As a result, D2 gastrectomy is preferred in Asia for
patients presenting with resectable gastric cancer [8].
Although surgery is the most efficient treatment for
operable cancer, recurrence may result in cases with
poor prognosis. As an important component of resectable
gastric cancer therapy, adjuvant chemotherapy could im-
prove patient outcomes, although no consensus about
the preferred treatment has been reached [9-11]. Ac-
cording to the guidelines of the National Comprehen-
sive Cancer Network (NCCN), both capecitabine plus
oxaliplatin and S-1 are recommended as adjuvant treat-
ments for gastric cancer [12].
Capecitabine is a new oral drug derived from fluoroura-
cil (FU), which is widely used in the therapy of breast,
gastrointestinal, and head and neck cancers [13-15]. Ais is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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effective and tolerable in patients with gastric cancer [16].
By contrast, S-1 is an orally active combination of tegafur,
gimeracil, and oteracil at a molar ratio of 1:0.4:1 and is
used as a novel mode of neoadjuvant chemotherapy
[2,17,18]. As relatively new adjuvant chemotherapies, both
modes of therapy have the potential to decrease recur-
rence rates and achieve survival benefits for patients com-
pared with surgery alone [19-21]. However, both modes of
therapy markedly increase the cost of the entire treatment
approach for gastric cancer, and widespread use of these
modes would be limited, particularly in health resource-
poor countries such as China [22].
Cost-effectiveness analyses can improve resource allo-
cation efficiency by identifying therapies that provide the
greatest health benefits at acceptable cost. However, clin-
ical trials that feature health economics assessments are
scarce. Therefore, we have used a mathematical model-
ing approach to conduct health economics analyses.
Within this study, we have developed a health econom-
ics model to evaluate the long-term cost-effectiveness of
two adjuvant chemotherapies (the adjuvant S-1 and
XELOX strategies) compared with surgery alone in pa-
tients presenting with gastric cancer and undergoing D2
gastrectomy in China. The model integrates the best avail-
able evidence in terms of costs and clinical outcomes
resulting from the use of adjuvant therapies to determine
whether such strategies truly represent a health budgetary
advantage in the context of the Chinese healthcare system.
Methods
Analytical overview and model structure
In this study, we used a Markov cohort model pro-
grammed using R software (version 2.15.1; R Develop-
ment Core Team, Vienna, Austria) to estimate and
compare the lifetime direct medical costs and health bene-
fits associated with surgery only or the use of the adjuvant
chemotherapies listed below for patients presenting with
gastric cancer after D2 gastrectomy. As shown in Figure 1,
there were 3 different health states according to the health
outcomes in the model: relapse-free survival (RFS), disease
recurrence, and death. The predominant adjuvant therap-
ies for gastric cancer patients, S-1 (the S-1 strategy) and
capecitabine plus oxaliplatin (the XELOX strategy), were
included in the treatment regimens, and the outcomes of
these therapies were compared with surgery only (Surgery
strategy). The future costs and benefits were discounted
using a 3% annual discount rate.
We assumed that the clinical characteristics of the
hypothetical gastric cancer cohorts were consistent with
published studies, which had a mean age of 59.5 [2,23].
The clinical stage of all gastric cancers was II or III, as
confirmed by pathology, and all patients underwent
curative D2 gastrectomy. The initial health status of thepatients was RFS. In the Markov models, one patient
was always in one of a series of different health states,
called Markov states. All events were represented as
movements from one state to another [24]. The cycle
length of the model was 1 week. At the completion of each
cycle, patients either remained in their assigned health
state or progressed to a new health state. The probability
of RFS and overall survival (OS) for patients in this model
were determined according to the RFS and OS survival
data reported in clinical trials [25].
Clinical data and adjusted indirect comparison
We performed a literature search of the following elec-
tronic databases to identify pivotal clinical trials pertaining
to adjuvant chemotherapies in patients presenting with
gastric cancer and undergoing D2 gastrectomy: PubMed,
EMBASE, CINAHL, AltHealthWatch, the Cochrane Li-
brary, and the National Library of Science and Technol-
ogy. The search encompassed the periods from database
inception to the end of July 2013. However, no clinical trial
directly comparing these three strategies was identified.
Therefore, an indirect comparison of key clinical trials
was performed. Clinical effectiveness data, including the
HR, were extracted from the two pivotal multicenter
randomized-controlled clinical trials where patients re-
ceived surgery only as a common comparator [2,23].
Each of these trials constituted level 1 evidence [26].
Weibull survival models were fitted to the Kaplan-
Meier RFS and OS data for surgery only. The transition
parameters and proportions were based on randomized
clinical trials to the greatest possible extent (Table 1).
The trial reported by the ACTS-GC Group random-
ized patients presenting with stage II or III gastric can-
cer who had undergone gastrectomy with extended (D2)
lymph-node dissection to surgery followed by adjuvant
therapy with S-1 (n = 530) or surgery alone (n = 529). OS
at 5 years was 71.7% in the S-1 group and 61.1% in the
surgery-alone group (HR, 0.669; 95% CI, 0.540-0.828).
RFS at 5 years was 65.4% in the S-1 group and 53.1% in
the surgery-alone group (HR, 0.653; 95% CI, 0.537-
0.793) [2].
In the CLASSIC trial, 1035 patients were randomized
(520 to receive oral capecitabine plus intravenous oxali-
platin and surgery compared with 515 to receive surgery
alone). Five-year disease-free survival (DFS) was 68% in
the chemotherapy and surgery group and 53% in the
surgery-alone group (HR, 0.58, 95% CI 0.47-0.72; P <
0.0001). Five-year OS was 78% in the XELOX group and
69% in the surgery-alone group (HR, 0.66, 95% CI 0.51-
0.85; P = .0015) [23,27].
Indirect comparisons of the three strategies were con-
ducted using the surgery-only survival rate from the re-
ports of the ACTS-GC Group as the reference because
the trial reported five-year outcomes. Weibull survival
Figure 1 Schematic depiction of the health economic model.
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data from the reports of the ACTS-GC Group for the
surgery-only strategy. The estimated Weibull scale (λ)
and shape (γ) parameters are shown in Table 1. The
Weibull survival curves of the two adjuvant strategies
were derived using the HRs, as previously described by
Hoyle, M. et al. [28]. The RFS and OS HRs between the
alternative adjuvant therapy strategies and surgery-only
strategy were derived from the previously mentioned
published studies.
Patients could die of natural causes during the RFS
period at any point beyond the time horizon of the trial
follow-ups. The model used a normal life table from the
life tables available to WHO member states (2011) to ad-
just the mortality risk for patients in RFS [29].Table 1 Clinical data
Parameters Values
Weibull survival model of RFS for surgery only
1-97 weeks Scale = 0.0015
Beyond 97 weeks Scale = 0.0275
Weibull survival model of OS for surgery only
1-141 weeks Scale = 0.0000
Beyond 141 weeks Scale = 0.0052
HR of RFS (compared with surgery only)
Adjuvant with S-1 0.653 (95% C
Adjuvant with XELOX strategy# 0.58 (95% CI:
HR of OS (compared with surgery only)
Adjuvant with S-1 0.669 (95% C
Adjuvant with XELOX strategy 0.66 (95% CI:
#We assumed that DFS in the CLASSIC trial was not better than RFS.Medical costs and utility
The collection of cost and utility data was approved by the
ethics committee of Renji Hospital, and the survey quali-
fied as involving only “minimal risks” to the participants.
The survey was completely anonymous, and questionnaire
responses were not linked with the participants’ identity in
the survey process. Verbal informed consent regarding the
goals of the study and willingness to participate was re-
ceived from the potential respondents. This procedure
was approved by the ethics committee of Renji Hospital.
Costs were estimated from the perspective of the
Chinese healthcare system and reported in 2013 US dol-
lar equivalents. The following direct medical cost com-
ponents were considered: treatment-related medicine,
monitoring and administration, inpatient care, palliativeDescription and reference
54; Shape = 1.202; r2 = 0.9955 [2]
4; Shape = 0.5736; r2 = 0.9792 [2]
5097; Shape = 1.755; r2 = 0.9977 [2]
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events. All unit costs of the health resources were esti-
mated using data from the local health system or the
National Development and Reform Commission (NDRC)
of China [30].
The estimated treatment costs were based on the fol-
lowing schedules for administration of S-1 or XELOX
strategies to patients with RFS after D2 gastrectomy. S-1
was administered as a dose of 40 mg/m2 twice each day
for 4 weeks, followed by 2 weeks of no chemotherapy;
this cycle was repeated for 1 year. The treatment regi-
men for the XELOX strategy consisted of eight 3-week
cycles, during which a 2-h intravenous infusion of oxalipla-
tin was given at a dose of 130 mg/m2 on day 1 and oral
capecitabine was given at a dose of 1000 mg/m2 twice daily
on days 1 to 14 of a 3-week cycle. The costs related to
SAEs and other costs in the course of adjuvant chemother-
apy were derived from a cost analysis study that reported
the monetary costs of the two regimens in Chinese gastric
cancer patients who had received adjuvant chemotherapy
[31]. After cancer progression, salvage chemotherapy and
supportive care were available. Approximately 13.5% pa-
tients received supportive care, and 86.5% patients received
salvage chemotherapy after disease relapse [25]. Based on
the literature and expert opinion, the median number of 3-
week treatment cycles was seven [25]. The overall costs re-
lated to salvage chemotherapy and supportive care were
estimated from 133 records of patients who presented with
recurrent gastric cancer and received salvage chemother-
apy or supportive care at four teaching hospitals in China
from January 2010 to April 2013 (the Renji Hospital, the
Second Hospital of Nanjing, the Taixing People’s Hospital
and the Yuxi People’s Hospital). To estimate the dosage of
the therapeutic agents, we assumed that a typical patient
weighed 65 kg and had a height of 1.64 m, resulting in a
body surface area (BSA) of 1.72 m2 [32]. To simplify the
model, we assumed that unused drugs in opened vials were
discarded. In addition, the current analysis included the
cost of palliative end-of-life care. This cost was esti-
mated from 42 records of patients who died from ad-
vanced gastric cancer.
The outcome used in this analysis was QALYs. Utility
scores ranged from 0.0 to 1.0, with 1.0 representing per-
fect health and 0.0 representing death. Two panels, one
comprising 36 patients with gastric cancer after D2 gas-
trectomy (disease duration: 4.5 ± 3.7 years) and one
comprising 50 patients with recurrent gastric cancer
(disease duration: 0.7 ± 0.5 years), were enrolled in the
study to complete an interview to empirically measure
the utility scores of each health state subgroup in the
model. This measurement was performed using the time
trade-off (TTO) elicitation technique, in which patients
were asked how many additional years they expected to
live and how many of those years (if any) they wouldtrade in return for receiving a technology that would
guarantee permanent perfect health, based on a standard
protocol derived from the methods reported by Redel-
meier DA [33]. Health state utility scores are listed in
Table 2. QALYs were estimated for each weekly cycle as
the number of patients in each health state multiplied by
their utility scores. Discounted QALYs that had accrued in
each cycle were summed over the lifetime years to deter-
mine the total discounted QALYs amassed by the cohort.
Sensitivity analysis
To evaluate the uncertainty of parameter values and the
robustness of the model, univariate sensitivity analyses
were performed for each parameter in the model over
the ranges. The results were presented as a tornado dia-
gram based on the impact of the variable on the incre-
mental net health benefit, using 1 × per capita GDP of
China as the cost-effectiveness threshold, according to
the World Health Organization (WHO) recommenda-
tion [34-36]. Probabilistic sensitivity analyses (PSA) were
used to simultaneously evaluate the impact of uncer-
tainty across all parameters, in which distributions were
assigned to the input parameters of the model (lognor-
mal distributions for costs, beta distributions for probabil-
ity parameters and utilities). Using these distributions,
1,000 iterations of 1,000 simulated patients were deter-
mined. The outcomes projected from all 1,000 simulations
were used to plot acceptability curves to estimate the




The model-derived survival probabilities calculated at spe-
cific time points satisfactorily matched those from the clin-
ical trial (Table 3). The RFS and OS data for the different
strategies at 3 years and 5 years varied from −5.9% to 2.1%
between the model outcomes and the trial data (Table 3).
The model outcomes did not exceed the 95% CI of the trial
data. Model-derived survival curves did not significantly
differ from the results of the clinical trials (Figure 2).
Base-case analyses
Our model estimated the costs and health outcomes of
the different strategies. The adjuvant XELOX strategy
yielded the greatest increase in QALYs over the course
of the disease (8.1 compared to 7.8 QALYs for the S-1
strategy and 6.2 for the surgery-alone strategy), which can
be largely explained by the RFS associated with each strat-
egy. Compared to adjuvant therapy with the S-1 strategy,
the incremental cost per QALY gained by using the
XELOX strategy was significantly lower: $3,502 vs. $6,837
(see Table 4 and Figure 2, and Table 4 and Figure 3,
respectively).
Table 2 Base-case cost estimates ($, year 2013 values) and utilities
Parameter Median Range Description and reference
Costs
Cost of capecitabine per 500 mg 6.6 Fixed Local charge
Cost of S-1 per 20 mg 9.6 7.9 - 10.1 Local charge
Cost of oxaliplatin per 50 mg 88.9 77.3 - 464.5 Local charge
Cost of follow-up per unit 56.5 42.3 - 70.6 Calculation
Cost of tests per 6-weeks of adjuvant with S-1 197.8 15.9 - 317.5 [31]
Cost of salvage chemotherapy per 3-week cycle 2334.6 1429.3 - 3323.2 Calculation
Cost of palliative end-of-life care 1460.3 1055.3 - 2085.7 Calculation
Cost of supportive care per cycle 115.2 31.7 - 317.5 Calculation
Cost of ADR per 6-week period of adjuvant with S-1 42.3 7.9 - 79.4 [31]
Cost of ADR per 3-week cycle of adjuvant with XELOX strategy 68.9 15.9 - 158.7 [31]
Cost of hospitalization per 3-week cycle of adjuvant with XELOX strategy 373 238.1 - 793.7 [31]
Utilities
Utility of disease-free survival 0.88 0.8 - 0.97 Measured
Utility of recurrent disease 0.42 0.28 - 0.63 Measured
Key: “&” Values were measured by time trade-off (TTO).
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The one-way sensitivity analysis revealed that some model
variables had a substantial impact on the results of adjuvant
therapy using the XELOX strategy compared with surgery
alone, including the HR of RFS and the costs of oxaliplatin
and supportive care (Figure 4). At the upper boundary of
the HR of RFS, the cost of oxaliplatin, the discount rate and
the cost per QALY gained ($) exceeds the very cost-
effective threshold ($6,100). Other factors, including the
HR of OS and costs related to supportive care, salvage
chemotherapy and the management of ADRs had moderate
or minimal impact on the cost per QALY gained. None ofTable 3 Survival probabilities from the model outcomes and
Model outcome
Disease-free survival
Surgery only at 3 years 60.8%
Adjuvant with S-1 at 3 years 72.3%
Adjuvant with XELOX strategy at 3 years 75.0%
Surgery only at 5 years 51.2%
Adjuvant with S-1 at 5 years 64.6%
Adjuvant with XELOX strategy at 5 years 67.9%
Overall survival
Surgery only at 3 years 72.2%
Adjuvant with S-1 at 3 years 80.4%
Adjuvant with XELOX strategy at 3 years 80.7%
Surgery only at 5 years 60.9%
Adjuvant with S-1 at 5 years 71.8%
Adjuvant with XELOX strategy at 5 years 72.1%the variable parameters lead to an ICER exceeding a value
of $18,300 per additional QALY gained (which represents
three times the per capita GDP of China).
The plot data from the PSA of 1,000 simulations re-
vealed the probabilities of meeting the ICER thresholds
of $6,100 per additional QALY for the XELOX strategy
compared with the S-1 and surgery-only strategies (see
Figure 5). The probabilities of achieving cost-effectiveness
with the XELOX strategy were more than two-thirds com-
pared with the S-1 and surgery-only strategies.
The cost-effectiveness acceptability curves (CEACs)
revealed the preferred strategies for gastric cancer whentrial data
Trial data Difference
59.6% (95% CI, 54.9 - 64.3%) 1.2%
72.2% (95% CI, 67.9 - 76.4%) 0.1%
74% (95% CI, 69 - 79%) 1.0%
53.1% (95% CI, 48.7 - 57.4%) −1.9%
65.4% (95% CI, 61.2 - 69.5%) −0.8%
68% −0.1%
70.1% (95% CI, 65.5 - 74.6%) 2.1%
80.1% (95% CI, 76.1 - 84.0%) 0.3%
83% (95% CI, 79 - 87%) −2.3%
61.1% (95% CI, 56.8 - 65.3%) −0.2%
71.7% (95% CI, 67.8 - 75.7%) 0.1%
78% −5.9%
Figure 2 Calibration curve for RFS and OS.
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(Figure 6). The CEAC plot demonstrated that the XELOX
strategy could achieve nearly two-thirds the likelihood of
cost-effectiveness when the threshold level was the per
capita GDP of China in 2012 ($6,100).
Discussion
The current analysis is the first to evaluate the health
and economic outcomes of different adjuvant regimens
in gastric cancer patients treated with D2 gastrectomy.
We determined that adjuvant therapies provide substan-
tial health benefits relative to surgery only by increasing
the QALYs (Table 4). This increase in QALYs, in turn,
could be contributed to improvements in the RFS and
OS rates [2,23]. The total costs associated with the use
of adjuvant chemotherapy for the S-1 and XELOX strat-
egies were $24,503.1 and $18,379.6, respectively, both of
which are significantly higher than the cost of surgery
only ($13,638.2). However, our cost-effectiveness analysis








Cost of relapse-free state 445.8 14,776.3 13,468.3
Cost of disease recurrent state 12,248.6 8,984.7 6,166.6
Cost of death from gastric cancer 1,174.8 1,101.4 1,091.7
Total cost ($) 13,638.2 24,503.1 20,331.6
QALYs 8.1 10.8 11.5
Incremental cost per QALY* 6,837 3,502
Key: “*” compared with Surgery only.versus the Surgery only strategy are $6,837 and $ 3,502,
respectively, per additional QALY gained. According to
the WHO recommendation for the cost-effectiveness
threshold, both adjuvant strategies are cost-effective be-
cause their ICERs are lower than the threshold of $18,300
per additional QALY gained (which represents three times
the per capita GDP of China in 2012) [34-36]. In particu-
lar, the ICER of the XELOX strategy in the base-case ana-
lysis was less than one times the per capita GDP of China
in 2012, indicating that adjuvant therapy with the XELOX
strategy would be very cost-effective in the Chinese setting
based on the WHO recommendation.
As shown in Table 4 and Figure 3, the XELOX strategy
may provide greater health benefits and relatively lower
costs compared with the S-1 strategy, indicating that the S-
1 strategy would be dominant. These results were further
confirmed by probabilistic sensitivity analyses and cost-
effectiveness acceptability curves (see Figures 5 and 6).
Only three other economic analyses of adjuvant
chemotherapy for the treatment of patients with stage
II-IIIB gastric cancer with D2 gastrectomy have been
conducted, all in Japanese or Chinese settings [37-39].
These reports determined that adjuvant chemotherapy
with S-1 or capecitabine plus oxaliplatin after D2 gas-
trectomy for patients with resectable gastric cancer was
a favorable recommendation in accordance with long-
term cost-effectiveness compared with D2 gastrectomy
alone. On the basis of the current clinical trial and from
the perspective of the Chinese healthcare system, the re-
sults of these studies are consistent with ours. However,
the result reported by Tan C et al. suggest that adjuvant
treatment with XELOX strategy is a cost-saving strategy
over the long term, despite the higher total cost of the
XELOX strategy compared with that of surgery alone.
Figure 3 The cost-effectiveness of strategies for gastric cancer patients. The oblique line connects surgery only and the most cost-effective
strategies. Strategies above the horizontal lines were dominated or extended dominated. In the cost-effective plane, the values of the most
incremental cost-effectiveness ratios (ICER) are shown.
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only strategy were $87,004 and $65,894, respectively, far
higher than our evaluation ($13,638.2) and the finding
($9,346) reported by Hisashige A et al. [37-39]. This dis-
crepancy may be due to the considerable assumptionFigure 4 A tornado diagram representing the net health benefits (in
one-way sensitivity analysis of the XELOX strategy vs. surgery only for patie
base-case value for the net health benefit with WTP = $6,100. Key: RFS (relamade by Tan C et al. that in the situation of tumor recur-
rence or new occurrences of gastric cancer, cycles of intra-
venous paclitaxel (at 80 mg/m2, three times per week)
would be administered every 4 weeks as a first-line chemo-
therapy for advanced gastric cancer [37,38]. However,QALYs with WTP = $6,100). The diagram was determined by a
nts presenting with gastric cancer. The vertical line represents the
pse-free survival); OS (overall survival); HR (hazard ratio).
Figure 5 The probabilistic results of the incremental cost-effectiveness difference. The XELOX, S-1, and surgery-only strategies were
compared. The y-axis represents the incremental costs. The x-axis represents the incremental QALYs gained. The ellipses surround 95% of the
estimates. The dots below the ICER threshold (the oblique lines) reflect simulations in which the cost per additional QALY gained for the XELOX
strategy was below the ICER threshold.
Figure 6 The cost-effectiveness acceptability curves for the three strategies. The y-axis indicates the probability that a strategy is
cost-effective across the WTP per QALY gained threshold (x-axis). The bold vertical dashed line represents the threshold for China.
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Comprehensive Cancer Network, clinical trials and our as-
sumptions in previous work, paclitaxel (80 mg/m2) is ad-
ministered as a second-line chemotherapy for advanced
gastric cancer and is repeated weekly for 3 of every 4 weeks
[12,40,41].
As reported by Tan C et al. the cost of oxaliplatin per
50 mg is a substantial consideration [37]. When brand-
name oxaliplatin (Eloxatin®, produced by Sanofi-Aventis)
was used in the XELOX strategy, the ICER of the
XELOX strategy increased to $10,469 per additional
QALY gained. The cost of generic oxaliplatin is only
one-quarter that of brand-name oxaliplatin, and the gen-
eric is now widely accepted and prescribed in Chinese
clinical practice. Although the sensitivity analysis indi-
cated that the XELOX strategy was cost-effective (using
brand-name oxaliplatin), we suggest the use of generic
oxaliplatin to further conserve limited healthcare re-
sources. Another important influential factor was RFS,
which would improve the ICER of the XELOX strategy
by decreasing the HR. This finding indicates that it is
more cost-effective to treat subgroups with more favor-
able prognostic factors, such as nodal status 1 or 2, with
the XELOX strategy compared with the Surgery strategy
[23]. The cost-effectiveness threshold of $18,300/QALY
was robust and revealed that treatment with an adjuvant
therapy using the XELOX strategy was cost-effective.
The results of this analysis must be interpreted care-
fully within the limitations of the data and study design.
First, we used a two-parameter Weibull survival model
to extend the tails of survival beyond the follow-up time
horizon [42]. Table 3 and Figure 2 show the estimated
survival rates fitted to the nonparametric Kaplan-Meier
survival rates from the trials, which support the validity
of our model. However, there are no long-term (>5 years)
RFS and OS data available for patients receiving adju-
vant chemotherapy, which could influence the results.
Although one-way sensitivity analyses were conducted
to evaluate the uncertainty in model outcomes arising
from the parameters, this lack of long-term data repre-
sents another limitation of our research approach. The
current analysis must be updated when long-term out-
comes are reported. Second, new therapies are rapidly be-
ing developed for managing gastric cancer, including
treatment with trastuzumab for HER2-positive gastric
cancer; this approach improved the survival of patients
with HER2-positive advanced gastric or gastro-esophageal
junction cancer [43]. However, these new agents tend to
be more expensive than current therapies. Although the
current analysis could not trace all medical resources asso-
ciated with potential new agents in the future, the findings
from the one-way sensitivity analyses indicate that the
ICER of adjuvant chemotherapy would be improved by in-
creased resource utilization after disease relapse. Third,owing to the absence of head-to-head trials for both of
the adjuvant strategies for the adjuvant therapy of gas-
tric cancer patients following D2 gastrectomy compared
in this study, an indirect comparison was conducted,
another inevitable weakness of the present analysis. The
patient characteristics in the CLASSIC trial and in the
trial reported by the ACTS-GC Group were assumed to
be similar in our indirect comparisons, and the results
of the indirect comparison were imputed into the ana-
lytical model. Nevertheless, as no data directly compar-
ing the effectiveness of the S-1 and XELOX strategies in
large RCTs are available, many investigators worldwide
accept indirect comparisons using robust methods. Fur-
ther studies will be required to directly determine the
clinical efficacy of these adjuvant strategies. Fourth, be-
cause of the absence of RFS data in the CLASSIC trial,
we replaced the RFS data with DFS data to compare the
outcomes of the XELOX and S-1 strategies. It could be
inferred that the XELOX strategy would have more a fa-
vorable RFS than the S-1 strategy because there are
more DFS than RFS events; events such as the develop-
ment of a second primary cancer would lead to more fa-
vorable economic outcome [44]. Fifth, the results of this
analysis should be carefully interpreted because several
factors such as the costs associated with death, the pat-
terns of clinical practice and the availability of health
care resources limit the transferability of economic eval-
uations across jurisdictions. Finally, owing to the nature
of the study design, we did not measure exact costs,
such as the costs associated with adverse events and
palliative care. A cost-of-illness study should be con-
ducted in the future. We believe that our results have
theoretical and reference value and provide valuable
policy-making data to guide the allocation of health re-
sources in China.Conclusions
Taken together, our results indicate that adjuvant therapy
with the S-1 or XELOX strategy is a cost-effective option
for gastric cancer after D2 gastrectomy and that the
XELOX strategy is potentially a very cost-effective alterna-
tive to the S-1 strategy or surgery alone, particularly when
generic oxaliplatin is used.Competing interests
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